PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 13, 2026AIP Advances0 citationsOpen Access

Tissue-composition-activated therapy: A Monte Carlo proof-of-concept for primary bone tumor treatment with lithium-6 ion beams

View Full Paper
JWJiaqi WangUniversity of Southern CaliforniaCZchuhan zhangJilin Province Science and Technology DepartmentCLChengqian LiJilin University

Key Points

  • This research aims to assess the therapeutic potential of lithium-6 ion beams for treating primary bone tumors.
  • Conducted high-statistics Geant4 Monte Carlo simulations to evaluate ion beam effects.
  • Tested lithium-6 ion beams at energies of 600–1200 MeV in 100 MeV increments.
  • Evaluated energy deposition and deuteron production in compact bone compared to soft tissue.
  • Demonstrated enhanced energy deposition of up to 5.984% at 1200 MeV in compact bone.
  • Increased deuteron production observed, reaching up to 1.395%.
  • Highlighted the potential for localized deuterium enrichment to impart tumor-suppressive effects.

Abstract

Exploring novel ion beams is an active research direction in medical physics. Lithium-6 (6Li), a weakly-bound nucleus, presents a unique opportunity for treating primary bone tumors by leveraging exothermic nuclear reactions with calcium in the bone microenvironment. This study employs high-statistics Geant4 Monte Carlo simulations to computationally evaluate the therapeutic potential of 6Li ion beams (600–1200 MeV, in 100 MeV steps). We reveal that 6Li ion beam irradiation of compact bone, compared to soft tissue, results in enhanced energy deposition (up to 5.984% at 1200 MeV) and a marked increase in deuteron production (up to 1.395%). This enhanced deuteron yield suggests a potential for localized deuterium enrichment, which, based on existing literature, imparts tumor-suppressive biological effects. Furthermore, the prominent 511 keV gamma peak observed underscores the inherent compatibility of this approach with positron emission tomography (PET) for treatment monitoring. Our findings establish 6Li ion as a unique therapeutic beam for bone tumor therapy. Leveraging its weakly bound nuclear structure, 6Li ion enables a dual-mechanism action that synergizes enhanced energy deposition with the in situ production of a tumor-suppressive agent (deuterium).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69b3ab9102a1e69014ccc7c9https://doi.org/10.1063/5.0312550
Ask AI
Helpful
Bookmark
Share
View Full Paper